24 August 2022 | Other

Moderna files FDA application for booster against Omicron variants

Moderna Inc. submitted the FDA request for a booster dose aimed at modern COVID-19 variants. The step is designed to ensure greater protection in fighting the virus.

The company claims the doses of Moderna’s booster, which are currently unrivaled on the market, ready to be dispatched in September. Only regulatory approval is needed. The vaccine is intended for adults over 18 years, designed to protect from the two dominant Omicron variants, BA.4 and BA.5.

Next week, the Centers for Disease Control and Prevention will stage a meeting. The main issue is expected to be Moderna’s booster shots. 

As of August 11, the company announced a clinical trial phase. Notably, UK regulators had already approved Moderna's bivalent booster against the early Omicron variant.

Company MarketCheese
Period: 21.05.2026 Expectation: 5000 pips
Investing in Tesla stock ahead of earnings report
Yesterday at 11:46 AM 35
Period: 28.04.2026 Expectation: 3550 pips
Buying BTCUSD with $78,300 target after overcoming local overbought conditions
Yesterday at 11:03 AM 23
Period: 28.04.2026 Expectation: 1170 pips
Investing in Brent crude with $107.00 in sight if sides fail to reach peace agreement
Yesterday at 10:01 AM 28
Period: 31.05.2026 Expectation: 800 pips
USDJPY struggles to climb above 160.00 resistance
Yesterday at 10:00 AM 16
Period: 30.04.2026 Expectation: 150 pips
Buy AUDUSD upon breaking 0.7185
Yesterday at 10:00 AM 12
Period: 21.06.2026 Expectation: 2700 pips
AUDUSD sell-off targets 0.69000
Yesterday at 09:52 AM 14
Go to forecasts